Science news articles about 'mdx'

... , multisite clinical trial to validate using Source MDx's six-gene CRPC Precision Profile(TM) ... of prostate cancer at all stages of the disease. Source MDx has filed provisional patents on the six-gene ...

... Health & Science University Cancer Institute researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The ...

... integrity. Mice lacking dystrophin, also known as mdx mice, are a model for Duchenne Muscular Dystrophy, ... high-level engraftment of transplanted SMPs in mdx animals shows therapeutic value—restoring ...

... to receive either intravenous placebo or intravenous administration of a combination of MDX-066 (CDA-1) ... of care antibiotics. In comparison with placebo, MDX-066/MDX-1388 treatment reduced recurrence ...

... -based diagnostic test developed by Source MDx in Boulder, Colo., both in terms of its sensitivity ( ... who don't have prostate cancer). Source MDx researchers developed the test after initially working ...

... radiation therapy. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a ...

... proportion of patients receiving ipilimumab may have long-term survival." Ipilimumab (also known as MDX-010 or MDX-101) is in a class of drugs called monoclonal antibodies, which stimulate the body's ...

... (dKO) mice, which present a much more severe and progressive dystrophic phenotype than mdx mice, could represent a more appropriate model to test the therapeutic potential of the antisense approach. ...